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Translational stallingCorrect folding of proteins is crucial for cellular homeostasis. More than thirty percent of proteins contain one or
more cofactors, but the impact of these cofactors on co-translational folding remains largely unknown. Here, we
address the binding of ﬂavin mononucleotide (FMN) to nascent ﬂavodoxin, by generating ribosome-arrested
nascent chains that expose either the entire protein or C-terminally truncated segments thereof. The native
α/β parallel fold of ﬂavodoxin is among the most ancestral and widely distributed folds in nature and exploring
its co-translational folding is thus highly relevant. In Escherichia coli (strain BL21(DE3) Δtig::kan) FMN turns out
to be limiting for saturation of this ﬂavoprotein on time-scales vastly exceeding those of ﬂavodoxin synthesis.
Because the ribosome affects protein folding, apoﬂavodoxin cannot bind FMN during its translation. As a result,
binding of cofactor to released protein is the last step in production of this ﬂavoprotein in the cell. We show that
once apoﬂavodoxin is entirely synthesized and exposed outside the ribosome towhich it is stalled by an artiﬁcial
linker containing the SecM sequence, the protein is natively folded and capable of binding FMN.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Proteins belong to the most important elements of a living cell. For
example, they confer stability in the form of the cytoskeleton, act as
biological catalysts and transporters, provide immune protection, and
are essential in cellular homeostasis [1]. An important aspect of homeo-
stasis is proteostasis, which not only encompasses the amount and dis-
tribution of proteins, but their correct folding aswell [2]. Protein folding
has been extensively studied in vitro and for some proteins folding
energy landscapes have been derived. Nowadays, focus has shifted to
understanding how proteins fold in vivo, which includes folding while
a protein is synthesized by the ribosome.Whereas ribosomal structures
have been elucidated in atomic detail (see e.g. [3–5]), relatively little is
known about the conformational events polypeptide chains undergo
while they are produced.
Several differences between in vitro and in vivo conditions may
affect protein folding, such as the dissimilarity between the dilute
environment of the test tube and the highly crowded condition in
cells [6]. In addition, a large fraction of cellular proteins comprise
chaperones, which prevent aggregation of newly synthesized proteinsvin adenine dinucleotide; RNC,
etic acid; GuHCl, guanidine
ierlo).
. This is an open access article under[1]. Moreover, the vectorial nature of polypeptide synthesis by the
ribosome can open up entirely new folding pathways.
Folding can already begin co-translationally, with only part of the
polypeptide chain synthesized, and has been investigated for protein
folds like all α [7–9], all β [10–13] and α/β [14–17]. Some proteins
seem to fold only when they are entirely exposed outside the ribosome
[12] orwhen they are released [18]. During synthesis, other proteins can
form folding intermediates [8,9,11,13,17,19], and protein subdomains
may properly fold while the remainder of the nascent sequence does
not [14,16]. In addition, the ribosome itself can in principle also modu-
late nascent chain folding [20].
Few nascent proteins investigated contain a cofactor in their native
state. This under-representation is undesirable, considering that at
least thirty percent of proteins have such a moiety [21]. Cofactors
range from metal ions to complexes like hemes, and organic moieties
such as ﬂavins. Heme has been suggested to bind to nascent globin
[7], which may imply that the protein folds co-translationally. Flavin
adenine dinucleotide (FAD) was proposed to covalently attach to
nascent 6-hydroxy-D-nicotine oxidase [22], but its co-translational
ﬂavinylation is now judged unlikely [23].
Most cofactors bind non-covalently, and in case of ﬂavoproteins
ninety percent bind ﬂavin in this way [24]. Flavoproteins make up to
three and a half percent of genes in certain genomes and fulﬁll many
important roles [24]. To reveal whether ﬂavin can bind to nascent
apo-protein, in this study we utilize a 179-residue ﬂavodoxin from
Azotobacter vinelandii. Flavodoxin is involved in electron transport in
the nitrate reduction cycle. For this purpose it uses a non-covalently,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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consists of ﬁve α-helices sandwiching a central parallel β-sheet, which
is an α/β parallel topology [26]. Approximately twenty-ﬁve percent of
proteins share this topology, according to SCOP classiﬁcation in the
Protein Data Bank (PDB). The ﬂavodoxin-like fold is among the most
ancestral folds [27] and is considered to be an archetype for the entire
class of αβα sandwiches. Though ﬂavodoxin is absent from plants and
animals [28], it is found in most algal lineages [29] and the ﬂavodoxin-
like fold is part of many multi-domain eukaryotic proteins such as
cytochrome P450 reductase [30] and nitric oxide synthase [31].
In vitro folding of full-length, isolated ﬂavodoxin involves two inter-
mediates: an on-pathway one, which is quickly converted into natively
folded apo-protein, and amolten globule species [32–35]. This species is
off the productive folding pathway and needs to unfold to embark on a
route to native protein [36]. The molten globule consists of a loosely
packed core and solvent exposed hydrophobic side chains [37–39]. For
many proteins with an α/β-parallel topology, formation of an
off-pathway intermediate seems to be a characteristic feature [40].
FMN binds to the ﬂavin-binding site of native apoﬂavodoxin. Besides
affecting this pocket, cofactor incorporation also inﬂuences thermody-
namic stabilities of residues faraway from the binding site [25].
Here, we report properties of nascent ﬂavodoxin. We prepare
ribosome-nascent chain complexes (RNCs) that expose either the entire
protein or C-terminally truncated segments of ﬂavodoxin outside the
exit tunnel. Use is made of constructs for ﬂavodoxin that lack zero,
ﬁve or ten amino acid residues at the C-terminus of the stalled polypep-
tide. This procedure allows themimicking of late periods during protein
translation and enables the elucidation of the stage at which nascent
apoﬂavodoxin is capable of binding FMN. Translational stalling is
made possible by attaching a sequence derived from Escherichia coli
SecM to the C-terminus of a nascent protein [41,42]. The RNCs are
isolated from E. coli strain BL21(DE3) Δtig::kan, which lacks chaperone
Trigger factor. We address FMN binding to nascent ﬂavodoxin by
titrating RNCs with FMN or by treating them with trichloroacetic acid
(TCA). It turns out that because the ribosome inﬂuences protein folding,
FMN cannot bind to apoﬂavodoxin during translation.
2. Materials and methods
2.1. Engineering RNCs
The construct for arrested, nascent protein, containing a triple
N-terminal StrepII-tag linked to a Smt3 domain, a multiple cloning site
(MCS), a TEV-site, a linker and a SecM stalling motif (Fig. 1A), was a
kind gift of Professor Elke Deuerling (University of Konstanz,
Germany) [12]. Ulp1 protease speciﬁcally recognizes Smt3 and cleaves
the polypeptide down-stream of Smt3, thereby producing nascent
ﬂavodoxin chains with Ala-1 as authentic N-terminus, if required. The
recognition site for TEV protease enables future release on demand of
nascent polypeptide. After the gene for ﬂavodoxin was cloned into the
MCS, two deletion variants of nascent protein were produced by using
the method described in [43]. These variants are shortened at the
C-terminus by ﬁve or ten amino acids, respectively. To avoid covalent
protein dimerization, the single cysteine at position 69 of ﬂavodoxin
was replaced by an alanine in all constructs [44]. Plasmids were
transformed in E. coli strain BL21(DE3)Δtig::kan for expression of RNCs.
2.2. Expression and puriﬁcation of RNCs
Based on the protocol described in [12], we developed the following
procedure. Cells were grown O/N in 50 ml Terriﬁc Broth (TB) with
100 μg/ml ampicillin at 37 °C while shaking at 140 rpm. Cells were
then pelleted at 5000 g for 10 min at 4 °C, re-suspended in 3 l of fresh
TB containing 100 μg/ml ampicillin and grown until an OD600 of 0.8.
For full-length construct, cells were pelleted at 11,000 g for 15 min at
4 °C. The pellet was re-suspended in 1 l of minimal (M9) mediumwith 100 μg/ml ampicillin and shaken for 1 h at 37 °C at 140 rpm.
Induction by 1 mM IPTG lasted 2.5 h. After reaching an OD600 of 0.8,
shortened constructs were induced by 1 mM IPTG for 1 h in TB. Cells
were subsequently pelleted at 11,000 g for 15 min at 4 °C and frozen
in liquid nitrogen.
Frozen cells were thawed and re-suspended in buffer I (50 mM
HEPES-KOH, 100 mM potassium acetate, 15 mM magnesium acetate,
1 mM dithiothreitol (DTT), pH 7.4) with added protease inhibitor
cocktail (Roche) and lysed by French Press. After centrifugation at
40,000 g for 30 min at 4 °C, supernatant was ﬁltered using a 0.22 μm
ﬁlter (EMD Millipore) and loaded onto a Strep-Tactin sepharose (IBA
GmbH) column, pre-equilibrated with buffer I. RNCs and released
protein were eluted with buffer I containing 2.5 mM desthiobiotin
(IBA GmbH). Eluate was concentrated with a 10-kDa spin ﬁlter (EMD
Millipore) at 5500 g and loaded onto a Superdex75 column to separate
RNCs from released constructs. Both fractionswere concentrated, frozen
in liquid nitrogen and stored at−80 °C.
Samples of each puriﬁcation step were analyzed by Coomassie-
stained SDS-PAGE orWestern blotting using either ﬂavodoxin antibody
raised in rabbits (Eurogentec) followed by anti-rabbit HRP-IG
(Eurogentec) or StrepMAB classic (IBA GmbH) against the N-terminal
StrepII-tag.
To determine whether binding of FMN releases nascent chains and
thus results in a different Superdex75 proﬁle, the above puriﬁcation
protocol was used with one modiﬁcation. The ﬁltered cell extract was
split in two and 50 μM FMN (Sigma) was added to one half. Both
samples were incubated on ice for 1 h.
2.3. FMN titration and TCA precipitation
To determine the extent of FMN occupation of RNCs and released
constructs, samples were made after Superdex75 puriﬁcation that
contain 0.5 to 1 μM of RNC or 2 to 3 μM of released protein in buffer I.
Samples were then split in two, of which one half was titrated with
FMN to determine its FMN-binding capacity using ﬂavin ﬂuorescence.
The other half was precipitated by adding 3% (w/v) TCA to establish
the total amount of FMN bound to protein. Precipitate was spun down
for 10min at 4 °C at 21,000 g and ﬂavin ﬂuorescence of the supernatant
was subsequentlymeasured. A 3 μMsolution of FMN in 3% (w/v) TCA in
buffer I was used as reference.
Flavin ﬂuorescence wasmeasured on a Cary Eclipse spectrophotom-
eter (Varian). Excitation was at 450 nm, with emission recorded
between 460 and 625 nm. Each sample was scanned 5 times and the
average was used for calculations. Excitation and emission slits were
set to a bandwidth of 5 nm. For RNCs the PMT voltage was 900 V,
whereas released protein was measured at 800 V.
2.4. Preparations of (truncated) apoﬂavodoxin variants
For production of apo-proteins, the constructs were loaded onto a
Superdex75 column containing 6 M guanidine hydrochloride (GuHCl;
Fluka) in its upper 20% volume. As a result, holo-protein unfolds and
releases FMN. Upon elution with buffer, apoﬂavodoxin and FMN
separate. Due tomigration into bufferwithout denaturant, apoﬂavodoxin
autonomously folds to native protein on-column, as its unfolding is
reversible [45].
3. Results
3.1. Production and puriﬁcation of RNCs
To assess cofactor binding during translation, we generated stalled
nascent chains of ﬂavodoxin. The corresponding constructs (Fig. 1A)
enable the tracking of nascent ﬂavodoxin folding outside the ribosome
at sequential stages of elongation. Nascent protein lacking none, ﬁve
or ten C-terminal amino acids of ﬂavodoxin, termed FL,−5 and−10
Fig. 1. Schematic representation of the construct for production of arrested, nascent
ﬂavodoxin and assessment of full-length and truncated RNCs of ﬂavodoxin. A) The gene
for production of RNCs consists of a triple N-terminal StrepII-tag (orange), an Smt3 do-
main (green) fused to ﬂavodoxin (yellow), a recognition site for TEV protease (blue)
and a ﬂexible hinge (i.e., GSGASGGAS) connected to a linker, which contains the SecM
stalling sequence (magenta) and spans the ribosomal exit tunnel. Through deletion of 5
or 10 residues at the C-terminus of ﬂavodoxin, respectively, 2 constructs are obtained
that produce stalled nascent proteins of speciﬁed length. B) Cartoon model of native
ﬂavodoxin (PDB ID 1YOB [1]) with FMN colored yellow. Flavodoxin's C-terminal 10 resi-
dues are highlighted in red. C) After induction in E. coli in M9 minimal medium, cell
lysis, and elution froma Strep-Tactin column, sampleswere loaded onto a Superdex75 col-
umn. The Superdex75 elution proﬁle of FLRNC and FLP, shows absorbance at 260 (red line)
and 280 nm(blue line). RNCs elute in the void volume,whereas released protein is retard-
ed, thus achieving separation of both species. D) Coomassie stained SDS-PAGE. Lanes
marked “Strep” show the mixture of RNCs and released proteins eluted from a Strep-
Tactin sepharose column. Lanes marked “RNC” display nascent protein eluted from a
Superdex75 column and illustrate the pattern typical for ribosomal proteins. Lanes
marked “free” show released protein (FL) and Smt3-domain with StrepII-tag attached
(Smt3). This domain is a degradation product of released protein. In (D) and (E), the po-
sition of nascent chain attached to tRNA is labeled (*) and the position of nascent chain
without tRNA is marked (**). The position of StrepII-tag attached to Smt3-domain is la-
beled (***). E) Western blots of RNCs and released proteins, with antibodies against
ﬂavodoxin (α-FLD) or the N-terminal StrepII-tag (α-strep). The 60-kDa band observed
in the RNC samples blotted withα-FLD is due to ribosomal protein that reacts withα-FLD.
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C-terminal α-helix of ﬂavodoxin, which packs onto the central
β-sheet of native protein (Fig. 1B). Expression of these constructs in
E. coli and subsequent puriﬁcation (see Materials and methods)
succeeded.
The SecM sequence allows for relatively tight stalling of nascent
chains [41]. However, some release of SecM-stalled nascent chains has
been documented both during production [17,46] and from puriﬁed
RNCs [12,47]. The mechanism that overcomes stalling in a cell is not
yet known. It has been suggested that physical force plays a role [41,
48,49]. We observe for all ﬂavodoxin constructs that release of stalled
nascent protein happens during production in E. coli. As a result,
Strep-Tactin column eluates contain RNCs (i.e., FLRNC,−5RNC,−10RNC,
respectively) and released protein (i.e., FLP,−5P,−10P, respectively).
To separate RNCs from released protein, we employ size-exclusion
chromatography (Fig. 1C). The absorbance ratio A260/A280 enables
distinction between RNCs and released ﬂavodoxin, as this ratio is ~2
for RNCs, while A260/A280 is b1 for released protein. Fig. 1D shows
assessment of the obtained fractions after Strep-Tactin and Superdex75column chromatography by Coomassie stained SDS-PAGE. The lanes
marked “Strep” display ribosomal protein bands arising from RNCs
and surplus released protein, i.e., FLP,−5P or a 18-kDa band containing
the StrepII-tag attached to Smt3, labeled (***). This 18-kDa band is an
in vivo degradation product of released protein, and its identity is
conﬁrmed by blots probed with antibodies against the StrepII-tag
(Fig. 1E). As the quantity of released protein is many times more than
the number of ribosomes in a cell, release of nascent chains likely occurs
during their production and not during their puriﬁcation. Co-elution of
released nascent chains with RNCs was excluded (see Supplementary
Figs. 1 and 2). The lanesmarked “RNC” show the typical pattern for ribo-
somal proteins and the presence of nascent protein, someofwhich is at-
tached to tRNA. Fig. 1D conﬁrms successful separation of RNCs from
released protein for all three constructs. Fig. 1E displays Western blot
bands detected with antibodies against StrepII-tag or ﬂavodoxin. The
lanes marked “α-FLD” show the presence of ﬂavodoxin in the fractions
containing RNCs or released proteins. As mentioned, some nascent
chains are coupled to tRNA, which results in observation of two bands
approximately 15 kDa apart in the lanes containing RNCs. Because a
polyclonal antibody is used to detect ﬂavodoxin, we observe differences
in afﬁnity for the constructs used. Highest afﬁnity is observed for FL, and
afﬁnity decreases in the order of −5 to −10. The lanes marked
“α-Strep” display a similar pattern for RNCs, showing nascent chain
with or without tRNA.3.2. Intracellular release of stalled nascent protein depends on growth
condition and chain length
Production of protein in E. coli at 37 °C in nutrient rich (i.e., TB) or in
minimal medium (i.e., M9) leads to similar amounts of FLRNC. However,
release of stalled nascent chains is much lower for cells grown in
minimal medium (Fig. 2A and B). A similar decrease in release of stalled
nascent chains is observedwhen RNC production in E. coli takes place in
nutrient rich medium at 20 °C (Fig. 2C and D). These observations
suggest that the more favorable the growth conditions are for E. coli,
the less effective SecM stalling becomes. To compensate for lower
synthesis rates during less favorable growth conditions, induction
times were increased from 1 h (for TB at 37 °C) to 2.5 h (for M9 at
37 °C or TB at 20 °C).
Another factor that inﬂuences the efﬁciency of ribosomal stalling
could be the length of the nascent chain. Fig. 3A shows observations
for FL construct. It is estimated that about 350 times more FLP than
FLRNC is present, based on absorbance at 280 and 260 nm, respectively.
Absorbance at 450 nm reveals that part of FLP contains FMN. In case
of−5 construct we observe less released nascent chains as compared
to released FL construct (Fig. 3B). The ratio of−5P to−5RNC is about
90. In case of −10 construct, we detect no released protein
(i.e.,−10P) (Fig. 3C). The−5 and−10 puriﬁcations all show separate
elution of StrepII-tag attached to Smt3 domain, as veriﬁed by Western
blotting with antibodies against StrepII-tag. Thus, both nascent chains
are rather unstable, because intracellular proteases can cleave off the
tagged N-terminal parts of these constructs. This degradation might
happen while the protein chain is attached to the ribosome and/or
after its release. As we obtain similar amounts of FLRNC, −5RNC and
−10RNC, which must have a StrepII-tag coupled to the nascent chain
during the ﬁrst step of puriﬁcation, degradation likely happens mostly
after release of the stalled nascent chain. However, as can be seen in
Fig. 1D, the intensity of the nascent chain in the−10RNC lane (at approx-
imately 40 kDa) is lower than the intensities corresponding to ribosom-
al proteins, indicating that some degradation of −10 nascent chain
happens during subsequent Superdex75 puriﬁcation. After puriﬁcation
we observe no further degradation of nascent chains and released
proteins during our experiments, which last only several hours at room
temperature. Clearly, the shorter the chain length of the C-terminus of
nascent ﬂavodoxin is, the more destabilized the protein becomes.
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Because we separate RNCs from released protein, a comparison of
their cofactor binding capacities can be made. First, we focus on
released ﬂavodoxin constructs. FLP and −5P both show absorbance
at 450 nm (Fig. 3A and B), indicating that FMN is bound. Binding of
FMN to native apoﬂavodoxin occurs primarily through a very speciﬁc
combination and geometry of hydrogen bonds and aromatic interac-
tions [25,50]. Thus, FMN-containing FLP and −5P must be natively
folded.
To assess remaining FMN binding capacity, we titrated released
protein from several puriﬁcation batches of E. coli with FMN (Fig. 4A).
Due to quenching of the ﬂuorescence of FMN upon binding to protein,
the slope of ﬂuorescence arising from bound FMN is less steep than
the slope from free FMN. This characteristic demonstrates FMN binding.
Both FLp and−5p were evaluated, whereas−10P was not, because of
degradation by proteases in E. coli. In case of FLP, FMN binding varies
strongly between batches. Quantiﬁcation of the amount of bound
FMN, derived by precipitating FLP with TCA andmeasuring ﬂuorescence
of released FMN, also shows considerable variation between batches.
FMN content of FLP ranges between 40 to 100% of protein population.
FMN synthesis is strictly regulated in E. coli and is only activated when
needed. Tomake FMN, the enzyme riboﬂavin kinase converts riboﬂavin
into FMN. Because most of the ribosomes in cells producing stalled
nascent chains are occupied, we assume that they synthesize less
riboﬂavin kinase and thus less FMN is made. Small variations during
growth may lead to alterations in the amount of riboﬂavin kinase and
thus FMN. As the amount of protein we produce is relatively small,
in terms of percentage, variation between batches can be large. Appar-
ently, a signiﬁcant fraction of apo-FLP resists intracellular proteolysis.
Of the−5P molecules 90–100% contain FMN according to TCA precipi-
tation. As a result, FMN titration of−5P shows no additional binding
of ﬂavin (Fig. 4A).Fig. 2.A switch fromnutrient rich tominimalmediumor from37 °C to 20 °Cduring induction af
all absorbance traces normalized relative to the maximum absorbance at 260 nm of FLRNC. Abs
column volume Vt. A) FLP produced in E. coli in Terriﬁc Broth after an induction period of 1 h at 3
37 °C. Compared to (A) thenumber of RNCs is unaltered, but release of stalled nascent chainshas
of 1 h at 37 °C. D) FLP produced in E. coli in Terriﬁc Broth after an induction period of 2.5 h at 20
has decreased considerably.The question arises why a higher proportion of−5P is observed to
be in the holo form than is the case for FLP. We note that the apo form
of −5P is more susceptible to degradation than apo-FLP, which is in
agreement with our observation that site-directed mutagenesis of
apoﬂavodoxin decreases the stabilities of the corresponding native
apo-proteins [38,45,51,52]. In addition, ﬂexibility of the ﬂavin-binding
site in ﬂavodoxin is much lower than in apoﬂavodoxin and holo-
protein is much more stable than apo-protein [25,53,54]. As a result,
contrary to apoﬂavodoxin, ﬂavodoxin is hardly degraded by proteases,
as trypsin digestion corroborates (Fig. 4C). For FLP it is possible to
prepare apo-protein, using GuHCl unfolding of the construct and its
subsequent refolding on a Superdex75 column (see Materials and
Methods). Apo-FLP shows the samedegradationpattern as apoﬂavodoxin
(Fig. 4C). The apo formof−5P could not be generated due to aggregation
of the sample during refolding, an indication of−5p's instability. A−5P
mimic was created by N-terminally moving the original stop codon of
ﬂavodoxin, generating a −5P without StrepII-tag, Smt3-domain and
SecM sequence. Upon overexpression, this −5P mimic is sequestered
into the insoluble part of cell lysate or degradedby proteases (see Supple-
mentary Fig. 3), whereas ﬂavodoxin is soluble and stable. This observa-
tion is another indication of the instability of−5P. During production of
stalled nascent chains the accompanying apo −5P is degraded by
proteases, whereas holo−5p is protected. Observation of the elution of
the isolated StrepII-tag attached to Smt3 supports this scenario
(Fig. 3B). As a result, in case of−5P 90–100% of puriﬁed, released nascent
chains contain FMN and are properly folded.
3.4. In E. coli (strain BL21(DE3)Δtig::kan) nascent ﬂavodoxin does not bind
FMN
In contrast to FLP and−5P, FLRNC and−5RNC shownoﬂuorescence of
free FMN after TCA precipitation. As none of the ribosomal proteins
contain FMN or FAD as cofactor, we conclude that during an inductionfects cellular release of stalled nascent protein. Shown are Superdex75 elution proﬁles,with
orbance at 450 nm tracks FMN incorporation. Elution volumes are normalized to the total
7 °C. B) FLP produced in E. coli inM9minimalmedium after an induction period of 2.5 h at
decreased considerably. C) FLP produced in E. coli in Terriﬁc Broth after an induction period
°C. Compared to (C), the number of RNCs is unaltered, but release of stalled nascent chains
Fig. 3. Comparison of release of shortened, stalled nascent chains. Shown are Superdex75
elution proﬁles with all absorbance traces normalized relative to the maximum absor-
bance at 260 nmof the respective RNCs. Absorbance at 450 nm tracks FMN incorporation.
Elution volumes are normalized to the total column volume Vt. All constructs are induced
for 1 h in E. coli in TBmedium. StrepII-tag attached to the Smt3 domain is labeled (Smt3).
A) FL construct produces FLRNC and FLP. B)−5 construct produces−5RNC,−5P and Smt3
domain. C)−10 construct produces−10RNC and Smt3 domain.
Fig. 4. Effect of FMN binding capacity on protection against proteolysis and release of na-
scent chains. For (A) and (B), observation of an altering slope in the titration data reveals
FMN binding. All ﬂuorescence is normalized to the ﬂuorescence of the end-point of the ti-
trated buffer sample. A) Titration of buffer, FLP and−5P with FMN. FLP preparations of
three E. coli batches have been used, labeled FLP1, FLP2 and FLP3, respectively. FLP1 and
FLP3 were induced in M9 minimal medium, whereas FLP2 was induced in TB medium.
FLP1 and−5P do not bind FMN, as they are already saturated. Concentrations of FLP and
−5P were between 2 to 3 μM. B) Titration of buffer, FLRNC and−5RNC with FMN. FLRNC
was induced in M9 minimal medium. −5RNC does not bind FMN and no ﬂuorescence
arises after TCA precipitation, therefore it cannot bind FMN. Concentrations of FLRNC and
−5RNC were between 0.5 and 1 μM. C) Puriﬁed holo and apo samples of ﬂavodoxin and
FLP (1 pmol/μl) are digested with trypsin (10 μg/ml). Samples are taken at 0, 3 and
7.5 min after trypsin addition and analyzed byWestern blot probed with anti-ﬂavodoxin.
While the respective apo-proteins are degraded within 3 min, holo protein resists prote-
olysis up to 7.5 min. The approximately 5-kDa downward shift of holo FLP observed be-
tween 0 and 3 min is due to proteolytic removal of triple strep-tag. The faint band in the
apo FLP samples of 3 and 7.5 min is a small remainder of holo FLP after preparation of
apo protein.
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ﬂavodoxin does not bind FMN during production in E. coli.
To reveal whether RNCs of ﬂavodoxin have intrinsic FMN-binding
capacity, we titrated them with FMN. Upon binding, FMN ﬂuorescence
is quenched, resulting in a difference in ﬂuorescence intensity between
free and bound FMN. The altering slope in the ﬂuorescence titration
data of FLRNC (Fig. 4B) shows that FMN binds to FLRNC. Non-native
folding states, like for example unfolded and molten globular
apoﬂavodoxin, do not show a change in slope of the titration data and
thus they do not bind FMN [50]. The titration data of Fig. 4B thus
demonstrate that ﬂavodoxin can obtain its native fold while fully
exposed outside the ribosome. Folding to native apoﬂavodoxin can
occur in vivo as well as in vitro, and consequently FMN binding also
happens in both conditions. It is unlikely that FMN titration inducesstructural rearrangements that permit FMN binding in stalled or
released apoﬂavodoxin and its C-terminally truncated variants. Only
natively folded apoﬂavodoxin is capable of binding FMN, because it
provides the required combination and geometry of hydrogen bonds
and aromatic interactions [25]. As FMN titration of −5RNC shows, in-
complete ﬂavodoxin polypeptide that emerges from the ribosomal
exit tunnel does not incorporate FMN (Fig. 4B). The corresponding
released product (i.e., −5P) does bind FMN (Fig. 4A). Docking of the
C-terminalα-helix of ﬂavodoxin onto the core of the protein is required
for binding of FMN, as several residues of thisα-helix are involved [25].
Thus, upon dissociation from the ribosome, the C-terminal α-helix
forms within −5P, with possibly some residues of the TEV linker
involved (Fig. 1A), enabling subsequent binding of FMN. FMN incorpo-
ration is also seen in the−5P mimic (which has no StrepII-tag, Smt3
and SecM sequence) though to a lesser degree (see Supplementary
Fig. 4). The difference in FMN binding capacities of−5RNC and−5P re-
veals that the ribosome affects nascent ﬂavodoxin folding and cofactor
binding.
The C-terminally fused SecM sequence, which is used as the stalling
sequence, does not constrain native folding of apoﬂavodoxin, because it
Fig. 5. Binding of FMN does not release stalled nascent FLp from ribosomes. Shown are
Superdex75 elution proﬁles with all absorbance traces normalized relative to the maxi-
mum absorbance at 260 nm of FLRNC. Absorbance at 450 nm tracks the incorporation of
FMN. Elution volumes are normalized to the total column volume Vt. A) FLRNC and FLP ob-
tained from cell extract of E. coli to which no excess FMN has been added. B) FLRNC and FLP
obtained from cell extract of E. coliwith an excess of 50 μM FMN.
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apoﬂavodoxin sequence (Fig. 1A). Using similar constructs, it has been
shown that the presence of the SecM sequence does not affect nascentFig. 6. Proposed model for co-translational ﬂavodoxin folding and cofactor binding. Flavodoxin
yellow. A) Full-length RNCs can fold while stalled to the ribosome (colored brown) and are cap
bind FMN. B)−5RNC does not acquire ﬂavodoxin's native fold while stalled to the ribosome. A
puriﬁcation of only the Smt3 domain. Or,−5P folds properly and binds FMN, which protects it
bosome. Released−10P is degraded by proteases, and as a result only the Smt3 domain is purSH3 domain and barnase, because they fold properly when fully
exposed outside the ribosome [12,15]. Indeed, full-length ribosome-
attached apoﬂavodoxin folds natively and binds FMN, as demonstrated
above.
3.5. Binding of FMN does not release FL protein from the ribosome
As FLRNC can bind FMN the question arises whether FMN binding
overcomes stalling. Incorporation of FMN stabilizes ﬂavodoxin by
about 7 kcal/mol [50] and this drop in free energy might sufﬁce to
dissociate SecM from the ribosome.
To test this hypothesis, 50 μM of FMN has been added to cell extract
obtained through lysis of E. coli cells expressing FL construct. This FMN
concentration is about 20 times the total concentration of released
protein and RNCs. Subsequent puriﬁcation of FLRNC and FLP happens
according to protocol. If FMN binding would release stalled nascent
chains, the ratio of released protein versus RNC should increase.
However, no such increase is observed within experimental error
(Fig. 5A and B). Incubation of puriﬁed FLRNC with excess FMN for 24 h
shows some release of stalled nascent chain, but no more than without
FMN. Clearly, binding of FMN does not dissociate FL protein from the
ribosome.
4. Discussion
Whereas the understanding of folding of isolated proteins in a test
tube is considerable, knowledge about how polypeptides fold while
they are synthesized by the ribosome is largely lacking. As the α/β
parallel architecture of ﬂavodoxin is a common structural design in
nature, and the ﬂavodoxin-like fold is a subdomain in various
multi-domain proteins, elucidating its nascent chain folding is highly
relevant.
Synthesis of the 179-residue ﬂavodoxin lasts about 9 s in E. coli
under optimal conditions, because the translation rate is about 20
amino acid residues per second [55]. Our data imply that, during an in-
duction period of up to 2.5 h, FMN in E. coli (strain BL21(DE3)Δtig::kan)
is limiting for saturating apoﬂavodoxin, because FLP and FLRNC can stilland Smt3-domain (PDB ID 1L2N) are colored blue and red, respectively. FMN is shown in
able of binding FMN. However, most nascent chains release as apoFLP, which subsequently
fter release,−5P either does not fold properly and is degraded by proteases, resulting in
against proteolytic degradation. C)−10RNC does not fold properly while stalled to the ri-
iﬁed.
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the presence of chaperones may affect folding of full-length
ribosome-attached apoﬂavodoxin in E. coli (strain BL21(DE3)
Δtig::kan), which could adversely inﬂuence FMN binding. We note
minute, sub-stochiometric amounts of chaperones DnaK and
GroEL/ES with mass spectrometry in puriﬁed samples of RNCs and
released proteins. Apoﬂavodoxin molecules that are unable to incorpo-
rate FMN explain why we previously observed less over-production in
E. coli (strain TG2) of protein variants of ﬂavodoxin (like e.g. F44Y,
W128F, W167F and W128F/W167F [38,56]) compared to wild-type
protein. During the 12 to 20 h lasting over-production of these protein
variants, cells have to produce a large amount of FMN to satisfy the
requirements for cofactor. As FMN synthesis is relatively slow, it takes
much longer to assemble all the protein in holo form than the time in
which the maximum of apo-protein is synthesized [57]. Due to amino
acid residue replacement, F44Y, W128F, W167F or W128F/W167F
apoﬂavodoxin variants are destabilized compared to wild-type protein
[38,45,51,52]. Thus, these apo-proteins aremore efﬁciently degraded by
intracellular proteases before they can take advantage of the stabiliza-
tion conferred through binding of FMN. For larger ﬂavoproteins the
timely incorporation of cofactor and thus stabilization of the protein
may be even more important, as larger (multi-domain) proteins often
do not refold efﬁciently once they have been unfolded [58].
Our study demonstrates that the ribosome affects cofactor binding
during birth of ﬂavodoxin, because translation emulators like−5RNC
cannot bind FMN (Fig. 6). The corresponding released protein construct
(i.e.,−5P) is shown to contain FMN. As a result, non-covalent binding of
cofactor to released apoﬂavodoxin is the last step in production of this
ﬂavoprotein in the cell. Full-length, isolated chains of proteins with an
α–β parallel native-state topology tend to temporarily misfold during
unassisted folding in vitro to their functionally active forms. This folding
defect causes the presence of molten globules, which are prone to
aggregation [32,37,40]. Whether the ribosome modulates formation of
molten globules of nascent ﬂavodoxin awaits further investigation.
Using a linker with a SecM stalling sequence, we have shown that
ﬂavodoxin is natively folded while fully exposed outside the ribosome
and that it can bind FMN (Fig. 6). Separate domains ofmulti-domain pro-
teins are expected to fold independently of each other during translation
[14]. For multi-domain proteins that contain a ﬂavodoxin-like fold as
subdomain, our work suggests that incorporation of cofactor probably
occurs co-translationally once this fold has fully emerged from the ribo-
some. This concept contributes to understanding proteostasis during
translation of cofactor containing, multi-domain proteins. Incorporation
of cofactors would hamper proteolytic degradation of nascent chains,
due to increased stability conferred by cofactor binding. Especially in
eukaryotes, where protein synthesis is much slower than in prokaryotes
(i.e., 3 instead of 20 amino acids per second [59]), such impediment of
proteolysis could increase protein production efﬁciency. Indeed, for
several ﬂavoproteins involved in diseases, a beneﬁcial effect has been
observed when the respective ﬂavin was supplemented [60].
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbapap.2015.06.004.
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